Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease.
Anna Kablak-ZiembickaRafał BadaczTadeusz PrzewłockiPublished in: Journal of clinical medicine (2022)
MicroRNAs (miRs) are promising diagnostic, prognostic and therapeutic biomolecules for atherosclerotic cardiovascular disease. Atherosclerotic occlusive disease concerns a large population of patients, carrying the highest incidence of fatal and non-fatal adverse events, such as myocardial infarction, ischemic stroke, and limb ischemia, worldwide. Consistently, miRs are involved in regulation and pathogenesis of atherosclerotic coronary artery disease (CAD), acute coronary syndromes (ACS), both with ST-segment (STEMI) and non-ST segment elevation myocardial infarctions (NSTEMI), as well as cardiac remodeling and fibrosis following ACS. However, the genetic and molecular mechanisms underlying adverse outcomes in CAD are multifactorial, and sometimes difficult to interpret for clinicians. Therefore, in the present review paper we have focused on the clinical meaning and the interpretation of various miRs findings, and their potential application in routine clinical practice.
Keyphrases
- coronary artery disease
- acute coronary syndrome
- percutaneous coronary intervention
- clinical practice
- cardiovascular disease
- left ventricular
- cardiovascular events
- end stage renal disease
- coronary artery bypass grafting
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- heart failure
- type diabetes
- palliative care
- genome wide
- patient reported outcomes
- gene expression
- dna methylation
- risk assessment
- single molecule
- climate change
- copy number
- aortic valve